Trial reportHandbook of experimental pharmacology2021
Gastrointestinal Uses of Botulinum Toxin.
Trial report in Handbook of experimental pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- The Comparative Study of the Effects of Botulinum Toxin Micro-droplet Injection Combined with Micro-crosslinked Sodium Hyaluronate Gel or Focused Ultrasound Technology in Facial Rejuvenation Treatment.Aesthetic plastic surgery · 2025Article
- Outlet type constipation in adult patients treated with type A botulinum toxin: a cohort study.International journal of colorectal disease · 2025Article
- Exploring New and Potential Indications for Botulinum Toxin Treatment: An Updated Literature Review.Cureus · 2024Review
- Recent Developments in Engineering Non-Paralytic Botulinum Molecules for Therapeutic Applications.Toxins · 2024Review
- Article
- Intragastric Botulinum Toxin Injection and Botulism: An Alarm for Clinicians.Case reports in critical care · 2024Article
- Botulinum Toxin A Use in the Gastrointestinal Tract: A Reappraisal After Three Decades.Gastroenterology & hepatology · 2023Article
- Botulinum toxin injection for the treatment of chronic anal fissure: uni- and multivariate analysis of the factors that promote healing.International journal of colorectal disease · 2022Article
- Comparison of safety and efficacy of intragastric botulinum toxin-A versus gastric balloon.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum toxin (BT), one of the most powerful inhibitors that prevents the release of acetylcholine from nerve endings, represents an alternative therapeutic approach for "spastic" disorders of the gastrointestinal tract such as achalasia, gastroparesis, sphincter of Oddi dysfunction, chronic anal fissures, and pelvic floor dyssynergia.BT has proven to be safe and this allows it to be a valid alternative in patients at high risk of invasive procedures but long-term efficacy in many disorders has not been observed, primarily due to its relatively short duration of action. Administration of BT has a low rate of adverse reactions and complications. However, not all patients respond to BT therapy, and large randomized controlled trials are lacking for many conditions commonly treated with BT.The local injection of BT in some conditions becomes a useful tool to decide to switch to more invasive therapies. Since 1980, the toxin has rapidly transformed from lethal poison to a safe therapeutic agent, with a significant impact on the quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.